Literature DB >> 31822780

Associations between primary aldosteronism and diabetes, poor bone health, and sleep apnea-what do we know so far?

Huai Heng Loh1, Norlela Sukor2.   

Abstract

Primary aldosteronism (PA), the most common cause of secondary hypertension, is a well-recognized condition that can lead to cardiovascular and renal complications. PA is frequently left undiagnosed and untreated, leading to aldosterone-specific morbidity and mortality. In this review we highlight the evidence linking PA with other conditions such as (i) diabetes mellitus, (ii) obstructive sleep apnea, and (iii) bone health, along with clinical implications and proposed underlying mechanisms.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31822780     DOI: 10.1038/s41371-019-0294-8

Source DB:  PubMed          Journal:  J Hum Hypertens        ISSN: 0950-9240            Impact factor:   3.012


  109 in total

1.  Laboratory investigation of primary aldosteronism.

Authors:  Michael Stowasser; Paul J Taylor; Eduardo Pimenta; Ashraf H Al-Asaly Ahmed; Richard D Gordon
Journal:  Clin Biochem Rev       Date:  2010-05

Review 2.  The renin-angiotensin-aldosterone system and calcium-regulatory hormones.

Authors:  A Vaidya; J M Brown; J S Williams
Journal:  J Hum Hypertens       Date:  2015-01-29       Impact factor: 3.012

3.  Improvement of bone turnover markers and bone mineral density following treatment of primary aldosteronism.

Authors:  Huai H Loh; Nor A Kamaruddin; Rozman Zakaria; Norlela Sukor
Journal:  Minerva Endocrinol       Date:  2016-12-20       Impact factor: 2.184

4.  Targeted treatment of primary aldosteronism - The consensus of Taiwan Society of Aldosteronism.

Authors:  Kuo-How Huang; Chih-Chin Yu; Ya-Hui Hu; Chin-Chen Chang; Chieh-Kai Chan; Shih-Cheng Liao; Yao-Chou Tsai; Shih-Chieh Jeff Chueh; Vin-Cent Wu; Yen-Hung Lin
Journal:  J Formos Med Assoc       Date:  2018-03-03       Impact factor: 3.282

5.  Role of unilateral adrenalectomy in bilateral primary aldosteronism: a 22-year single center experience.

Authors:  Norlela Sukor; Richard D Gordon; Yee Kim Ku; Mark Jones; Michael Stowasser
Journal:  J Clin Endocrinol Metab       Date:  2009-04-28       Impact factor: 5.958

6.  Does the treatment of primary hyperaldosteronism influence glucose tolerance?

Authors:  B Strauch; J Widimský; G Sindelka; J Skrha
Journal:  Physiol Res       Date:  2003       Impact factor: 1.881

Review 7.  Oxidative stress, endothelial dysfunction and atherosclerosis.

Authors:  Victor M Victor; Milagros Rocha; Eva Solá; Celia Bañuls; Katherine Garcia-Malpartida; Antonio Hernández-Mijares
Journal:  Curr Pharm Des       Date:  2009       Impact factor: 3.116

8.  Fasting plasma glucose and serum lipids in patients with primary aldosteronism: a controlled cross-sectional study.

Authors:  Joanna Matrozova; Olivier Steichen; Laurence Amar; Sabina Zacharieva; Xavier Jeunemaitre; Pierre-François Plouin
Journal:  Hypertension       Date:  2009-02-16       Impact factor: 10.190

9.  Aldosterone suppresses insulin signaling via the downregulation of insulin receptor substrate-1 in vascular smooth muscle cells.

Authors:  Hirofumi Hitomi; Hideyasu Kiyomoto; Akira Nishiyama; Taiga Hara; Kumiko Moriwaki; Kumiko Kaifu; Genei Ihara; Yoshiko Fujita; Toyomu Ugawa; Masakazu Kohno
Journal:  Hypertension       Date:  2007-07-23       Impact factor: 10.190

10.  Renal sympathetic denervation suppresses postapneic blood pressure rises and atrial fibrillation in a model for sleep apnea.

Authors:  Dominik Linz; Felix Mahfoud; Ulrich Schotten; Christian Ukena; Hans-Ruprecht Neuberger; Klaus Wirth; Michael Böhm
Journal:  Hypertension       Date:  2012-05-14       Impact factor: 10.190

View more
  3 in total

1.  Serum Metabolomic Patterns in Patients With Aldosterone-Producing Adenoma.

Authors:  Yule Chen; Hanjiang Wang; Ke Wang; Guodong Zhu; Zhishang Yang; Min Wang; Wenbin Song
Journal:  Front Mol Biosci       Date:  2022-04-08

2.  Clinical and biochemical predictors and predictive model of primary aldosteronism.

Authors:  Worapaka Manosroi; Natthanan Tacharearnmuang; Pichitchai Atthakomol
Journal:  PLoS One       Date:  2022-08-05       Impact factor: 3.752

Review 3.  Primary aldosteronism and obstructive sleep apnea: What do we know thus far?

Authors:  Huai Heng Loh; Norlela Sukor
Journal:  Front Endocrinol (Lausanne)       Date:  2022-09-29       Impact factor: 6.055

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.